These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2396173)

  • 1. [Neutropenia and hypotension during treatment with recombinant human erythropoietin in refractory anemia with ring sideroblasts].
    Benzadón RJ; Gurfinkel EP
    Sangre (Barc); 1990 Jun; 35(3):238-9. PubMed ID: 2396173
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant erythropoietin for refractory anemia with ring sideroblasts.
    Musto P; Catalano L; Andriani A; Bodenizza C; Cascavilla N; Di Renzo N; Melillo L; Cicoira L; Carotenuto M; Rotoli B
    Haematologica; 1992; 77(2):185-6. PubMed ID: 1398306
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin].
    Rodríguez JN; Prados D; Martino ML; Muñiz R
    Sangre (Barc); 1993 Aug; 38(4):340-1. PubMed ID: 8235952
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients.
    Kokot F; Wiecek A; Grzeszczak W; Klepacka J; Klin M; Lao M
    Contrib Nephrol; 1989; 76():257-70; discussion 270-2. PubMed ID: 2582782
    [No Abstract]   [Full Text] [Related]  

  • 5. Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome.
    Kardos G; Veerman AJ; de Waal FC; van Oudheusden LJ; Slater R
    Med Pediatr Oncol; 1996 Jan; 26(1):54-6. PubMed ID: 7494512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis.
    Tefferi A; Al-Kali A; Begna KH; Patnaik MM; Lasho TL; Rizo A; Wan Y; Hanson CA
    Blood Cancer J; 2016 Mar; 6(3):e405. PubMed ID: 26967822
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression.
    Broun ER; Greist A; Tricot G; Hoffman R
    JAMA; 1990 Sep; 264(11):1441-3. PubMed ID: 2094240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erythropoietin in the prevention and treatment of anemias (a review of the literature)].
    Shevchenko IuL; Danil'chenko VV; Zhiburt EB; Serebrianaia NB; Khubulava GG; Belevitin AB
    Voen Med Zh; 1996 Nov; 317(11):45-8. PubMed ID: 9036631
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
    Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
    Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 18. [Phase II clinical study of recombinant human erythropoietin on the anemia of myelodysplastic syndrome].
    Urabe A; Mizoguchi H; Takaku F; Miyazaki T; Yachi A; Niitsu Y; Miura Y; Mutoh Y; Fujioka S; Nomura T
    Rinsho Ketsueki; 1993 Aug; 34(8):928-36. PubMed ID: 8411647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erythropoietin as a therapeutic agent. II: Indications, side effects and dangers].
    Stasiecki P; Pollok M; Baldamus CA
    Med Klin (Munich); 1989 Apr; 84(4):216-8. PubMed ID: 2657364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.